The safety of blood thinners is an important consideration for many patients, as they are often prescribed to reduce the risk of stroke and other cardiovascular events.
A new study published in November 2022 in Annals of Internal Medicine has found that apibaxan is the safest blood thinner among the direct oral anticoagulants (DOACs), including dabigatran, edoxaban and rivaroxaban.
The study compared the safety of the four DOACs in over 10,000 patients with atrial fibrillation, a common heart rhythm disorder. The researchers found that apibaxan was associated with the lowest risk of gastrointestinal bleeding, a common side effect of blood thinners. Apibaxan was also associated with the lowest risk of major bleeding, including intracranial and gastrointestinal bleeding.
The study also found that apibaxan was associated with the lowest risk of thromboembolic events, such as stroke and deep vein thrombosis. The researchers concluded that apibaxan is the safest DOAC for patients with atrial fibrillation.
The findings of this study are important for patients who are taking blood thinners. Apibaxan is the safest DOAC for patients with atrial fibrillation, and it is associated with the lowest risk of gastrointestinal bleeding and other major bleeding events. Patients should discuss their individual risks and benefits with their doctor before starting a blood thinner.
In conclusion, the study published in November 2022 in Annals of Internal Medicine found that apibaxan is the safest blood thinner among the DOACs, including dabigatran, edoxaban and rivaroxaban. Apibaxan was associated with the lowest risk of gastrointestinal bleeding and other major bleeding events. Patients should discuss their individual risks and benefits with their doctor before starting a blood thinner.